Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis

Launched by COMMUNITY MEDICAL CENTER, TOMS RIVER, NJ · Oct 28, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the use of intravenous (IV) lidocaine as a pain relief option for adults with sickle cell disease who are in a painful crisis. Sickle cell disease can cause severe pain, often requiring treatment with opioids, which are powerful pain medications. However, due to the ongoing opioid crisis, there is a need to find alternative ways to manage pain effectively. The trial aims to see if adding IV lidocaine to the usual opioid treatment can help reduce pain and lower the total amount of opioids needed during a visit to the emergency department.

To participate in this study, you must be over 18 years old and have sickle cell disease with severe pain (rated 7 to 10 out of 10) that hasn't improved after receiving at least one dose of an opioid. Unfortunately, individuals under 18, pregnant women, or those with certain medical conditions won't be eligible. If you qualify and choose to participate, you can expect to receive both lidocaine and opioids to see how well they work together for your pain relief. This trial is important because it could help improve pain management for sickle cell patients while also addressing concerns about opioid use.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients \> 18 years old with sickle cell disease experiencing persistent severe (7-10/10) pain despite receiving at least one dose of intravenous opiate analgesic.
• Exclusion Criteria:
• • Patients \< 18 years old and pregnant
• • Patients presenting with or suspected to have acute chest syndrome
• • Allergy or intolerance to lidocaine products or morphine/hydromorphone